Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avila Therapeutics, Inc.

http://www.avilatx.com/

Latest From Avila Therapeutics, Inc.

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

Commercial Companies

Clovis Highlights Pipeline Turnaround Going Into 2014

The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.

BioPharmaceutical Clinical Trials

Clovis Highlights Pipeline Turnaround Going Into 2014

The small oncology company has recovered from previous setbacks and is now anticipating a strong year to come as it moves two drugs into later-stage development and pivotal trials.

BioPharmaceutical North America

For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon

A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

BioPharmaceutical United States
See All

Company Information

UsernamePublicRestriction

Register